5th Annual RAS-Targeted Drug Development Summit
Personalizing Medicine Via Targeting Oncogenic RAS for Cancer
With the approval of the second-ever KRAS G12C inhibitor, the field can once again celebrate irrevocable proof that RAS is druggable! However, with so many KRAS G12C drugs in clinic, the field is now turning its eyes to the next gener
26-28 September 2023